| Shala Cole, PSYD | |
|
956 Walnut St Ste 200, San Luis Obispo, CA 93401-1707 | |
| (805) 222-6807 | |
| Not Available |
| Full Name | Shala Cole |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 956 Walnut St Ste 200, San Luis Obispo, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043915978 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY31816 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shala Cole, PSYD 956 Walnut St Ste 200, San Luis Obispo, CA 93401-1707 Ph: (805) 222-6807 | Shala Cole, PSYD 956 Walnut St Ste 200, San Luis Obispo, CA 93401-1707 Ph: (805) 222-6807 |
News Archive
A new study aimed to identify COVID-19 vaccination coverage, examine the factors responsible for COVID-19 vaccination coverage and vaccine hesitancy, study adverse events following immunization patterns after COVID-19 vaccination and determine the prevalence of breakthrough infection after COVID-19 vaccination.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announces its schedule for filing with the U.S. government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy and RecoveryRx™ products. In these applications BioElectronics will seek over-the-counter clearance of its ActiPatch Therapy product for indications for the treatment of heel and foot pain, and for pain relief relative to general musculoskeletal complaints.
The U.S. Food and Drug Administration has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.
New research from the University of Sheffield has revealed that the molecular mechanism underlying deafness is caused by a mutation of a specific microRNA called miR-96. The discovery could provide the basis for treating progressive hearing loss and deafness.
A University of Louisville-led research team studying the face transplant has developed guidelines it says are critical to the success of the still-untried procedure.
› Verified 6 days ago
Dr. Cheryl Wilson Steed, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: Highway 1, San Luis Obispo, CA 93409 Phone: 805-547-7900 | |
Dr. Jay Bettergarcia, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1 Grand Ave, San Luis Obispo, CA 93407 Phone: 805-225-6406 | |
Dr. William A Dahlstrom, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: Highway 1 California Men's Colony, San Luis Obispo, CA 93409 Phone: 805-547-7900 | |
Dr. Mary L Malik, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1110 California Blvd Ste A, San Luis Obispo, CA 93401 Phone: 805-541-2490 | |
Dr. Michael Selby, PH.D., MCP Psychologist Medicare: Medicare Enrolled Practice Location: 1201 Leff St, San Luis Obispo, CA 93401 Phone: 805-439-0377 | |
Dr. Margaret E O'neill, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1299 Briarwood Dr, Apt 112, San Luis Obispo, CA 93401 Phone: 805-439-0156 |